UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2021-07, Vol.32 (7), p.839-853

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions

Cancer treatment reviews, 2018-03, Vol.64, p.21-29

2018

Volltextzugriff (PDF)

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients

British journal of cancer, 2017-10, Vol.117 (8), p.1128-1138

2017

Volltextzugriff (PDF)

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: A new era begins

Cancer treatment reviews, 2014-02, Vol.40 (1), p.93-101

2014

Volltextzugriff (PDF)

Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

Cancer treatment reviews, 2015-01, Vol.41 (1), p.27-34

2015

Volltextzugriff (PDF)

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

The European respiratory journal, 2011-03, Vol.37 (3), p.624-631

2011

Volltextzugriff (PDF)

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Cancer treatment reviews, 2018-12, Vol.71, p.47-58

2018

Volltextzugriff (PDF)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

Clinical & translational oncology, 2019-01, Vol.21 (1), p.3-17

2019

Volltextzugriff (PDF)

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Annals of oncology, 2023-05, Vol.34 (5), p.468-476

2023

Volltextzugriff (PDF)

Prehabilitation for patients undergoing neoadjuvant therapy prior to cancer resection: a systematic review and meta-analysis

Supportive care in cancer, 2024-11, Vol.32 (11), p.749, Article 749

2024

Volltextzugriff (PDF)

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Annals of oncology, 2018-10, Vol.29 (10), p.2121-2128

2018

Volltextzugriff (PDF)

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

Annals of oncology, 2020-02, Vol.31 (2), p.274-282

2020

Volltextzugriff (PDF)

IBS02.01 Making Sense of Treatment with so Many Options: My Algoritm — A European View

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S90-S90

Reguart, N.

2019

Volltextzugriff (PDF)

Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients

European journal of nuclear medicine and molecular imaging, 2021-10, Vol.48 (11), p.3631-3642

2021

Volltextzugriff (PDF)

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Lung cancer (Amsterdam, Netherlands), 2022-02, Vol.164, p.8-13

2022

Volltextzugriff (PDF)

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.83-90

2020

Volltextzugriff (PDF)

Beyond EGFR TKI in EGFR -mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

Cancer treatment reviews, 2014-07, Vol.40 (6), p.723-729

2014

Volltextzugriff (PDF)

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

Clinical & translational oncology, 2016-02, Vol.18 (2), p.153-159

2016

Volltextzugriff (PDF)

Sleeve lobectomy after induction chemoradiotherapy

European journal of cardio-thoracic surgery, 2012-05, Vol.41 (5), p.1052-1058

2012

Volltextzugriff (PDF)

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032

Annals of oncology, 2018-10, Vol.29, p.viii725-viii725

2018

Volltextzugriff (PDF)

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii741-viii742

2018

Volltextzugriff (PDF)

Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)

Revue des maladies respiratoires actualités, 2023-01, Vol.15 (1), p.127-128

2023

Volltextzugriff (PDF)

Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib

Journal of investigational allergology & clinical immunology, 2015-01, Vol.25 (4), p.307-308

2015

Volltextzugriff (PDF)

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial

Journal francais d'ophtalmologie, 2018-12, Vol.41 (10), p.955-962

2018

Volltextzugriff (PDF)

1 – 25 von 198

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(191)

Publikationsform

Artikel
(198)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(50)
Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Oncology
(35)
Lung Neoplasms - Drug Therapy
(22)
Biological And Medical Sciences
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(17)
Female
(16)
Medical Sciences
(16)
Lung Neoplasms - Genetics
(15)
Male
(15)
Middle Aged
(14)
Aged
(13)
Carcinoma, Non-Small-Cell Lung - Genetics
(12)
Mutation
(11)
Pneumology
(11)
Treatment Outcome
(11)
Adult
(10)
Lung Neoplasms - Pathology
(10)
Tumors
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: A new era begins

Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Prehabilitation for patients undergoing neoadjuvant therapy prior to cancer resection: a systematic review and meta-analysis

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

IBS02.01 Making Sense of Treatment with so Many Options: My Algoritm — A European View

Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Beyond EGFR TKI in EGFR -mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

Sleeve lobectomy after induction chemoradiotherapy

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)

Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial

Suchergebnisse filtern